Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 49 Suppl 2, 22-7

Megestrol Acetate in the Treatment of Metastatic Carcinoma of the Prostate

Affiliations
Review

Megestrol Acetate in the Treatment of Metastatic Carcinoma of the Prostate

P Venner. Oncology.

Abstract

Although current hormonal therapy of prostate cancer may not appear to have altered survival appreciably, there have been considerable changes that may significantly affect the future management of this disease. A number of new hormonal agents have been introduced that still require definition of their therapeutic efficacy. Megestrol acetate, a hormonal agent with multiple sites of action in androgen metabolism, has recently been investigated in the treatment of patients with metastatic and locally advanced disease, and in those patients whose disease progresses with other hormonal therapies. Megestrol acetate plus mini-dose diethylstilbestrol (DES) is associated with fewer side effects than standard-dose DES and has equivalent therapeutic efficacy in the treatment of patients with metastatic disease. In patients with locally advanced disease that may benefit from hormonal cytoreduction, megestrol acetate is effective and well tolerated. Megestrol acetate has a role in the palliation of patients with progressive disease despite initial hormonal therapy. Considerable controversy surrounds the therapy of carcinoma of the prostate; further studies are required to define optimal hormonal therapy.

Similar articles

  • Therapeutic Options in Treatment of Advanced Carcinoma of the Prostate
    PM Venner. Semin Oncol 17 (6 Suppl 9), 73-7. PMID 2259929.
    Considerable controversy continues to surround the therapy of metastatic carcinoma of the prostate. Until recently orchiectomy and diethylstilbestrol (DES) were the only …
  • Megestrol Acetate Plus Low-Dose Estrogen in the Management of Advanced Prostatic Carcinoma
    J Geller. Urol Clin North Am 18 (1), 83-91. PMID 1825145.
    Megestrol acetate plus low-dose estrogen may be an effective, low-cost alternative to pharmacologic or surgical castration plus flutamide in the management of patients wi …
  • Megestrol Acetate in Relapsed Carcinoma of Prostate
    F Daniel et al. Br J Urol 65 (3), 275-7. PMID 2186841. - Clinical Trial
    A series of 22 patients with advanced carcinoma of the prostate who had failed first-line hormonal therapy (orchiectomy, stilboestrol, luteinising hormone-releasing hormo …
  • Megestrol Acetate: Clinical Experience
    L Schacter et al. Cancer Treat Rev 16 (1), 49-63. PMID 2471590. - Review
    The use of megestrol acetate in treatment of malignancy (endometrial carcinoma, ovarian cancer, prostate cancer, breast cancer, renal cell carcinoma, malignant melanoma), …
  • Antiandrogenic Drugs
    DG McLeod. Cancer 71 (3 Suppl), 1046-9. PMID 8428326. - Review
    Currently, antiandrogens are used primarily in conjunction with conventional medical or surgical castration to achieve maximal androgen deprivation; however, ongoing clin …
See all similar articles

Cited by 1 PubMed Central articles

Feedback